TOI Projects Total Revenue of $650 Million for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation revenue in 2026. This expected top-line increase reflects continued expansion of delegated contracts in Florida, the annualized impact of strong volumes in the Dispensary segment during the second half of 2025, and broader organic growth and new contract wins across the platform.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TOI
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 6.67 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.000
Low
5.00
Averages
6.67
High
8.00
Current: 3.000
Low
5.00
Averages
6.67
High
8.00
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
M33 Growth Partners with US Neurology Associates to Transform Neurology Care
- Strategic Partnership: M33 Growth partners with US Neurology Associates to enhance the quality of neurology care by integrating resources and infrastructure to meet the growing patient demand.
- Leadership Team: Nitin Jain as CEO and Brad Hively as Chairman bring extensive management experience in healthcare, which will drive the company's growth.
- Innovative Care Platform: USNA will deliver comprehensive care including in-office infusions, diagnostics, and clinical trials, aiming to improve patient experience and reduce care costs through a one-stop service.
- Value-Oriented Approach: USNA is committed to collaborating with payers to promote value-based care models, aiming to provide efficient and cost-effective neurology solutions through integrated community clinics.
Continue Reading
The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care
- Leadership Changes: The Oncology Institute has appointed Rakesh Panda as Chief Information Officer, leveraging over 25 years of IT and digital transformation experience to advance the company's technology strategy, particularly in AI and data privacy, aimed at enhancing value-based cancer care.
- HR Strengthening: Nolan Mariano has been appointed Chief People Officer, overseeing HR operations and talent acquisition, and with 18 years of industry experience, he will enhance company culture and employee development to support the rapid growth of The Oncology Institute.
- Technology-Driven Care Platform: The new CIO will focus on the technology-enabled care delivery platform, driving innovations to improve patient experience and care quality, thereby strengthening the company's competitive position in the cancer care market.
- Sustained Growth Strategy: CEO Daniel Virnich emphasized the promotion of internal leaders, indicating the company's commitment to providing world-class community-based cancer care while continuing to experience rapid growth, further solidifying its leadership position in the industry.
Continue Reading